First human trial for ABBV-1451 begins in healthy volunteers
NCT ID NCT07570147
First seen May 10, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This study is the first time ABBV-1451 is given to humans. It aims to check the drug's safety, how the body processes it, and whether it triggers an immune response. About 90 healthy adults, including Japanese and Han Chinese participants, will receive a single dose. This is an early-stage trial with no direct treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Acpru /Id# 282128
Grayslake, Illinois, 60030, United States
Conditions
Explore the condition pages connected to this study.